BACKGROUND AND OBJECTIVES: Low circulating 25-hydroxyvitamin D [25(OH)D] and high sodium intake are both associated with progressive albuminuria and renal function loss in CKD. Both vitamin D and sodium intake interact with the renin-angiotensin-aldosterone system. We investigated whether plasma 25(OH)D or 1,25-dihydroxyvitamin D [1,25(OH)2D] is associated with developing increased albuminuria or reduced renal function and whether these associations depend on sodium intake. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Baseline plasma 25(OH)D and 1,25(OH)2D were measured by liquid chromatography tandem mass spectrometry, and sodium intake was assessed by 24-hour urine collections in the general population-based Prevention of Renal and Vascular End-Stage Disease cohort (n=5051). Two primary outcomes were development of urinary albumin excretion >30 mg/24 h and eGFR (creatinine/cystatin C-based CKD Epidemiology Collaboration) <60 ml/min per 1.73 m(2). Participants with CKD at baseline were excluded. In Cox regression analyses, we assessed associations of vitamin D with developing increased albuminuria or reduced eGFR and potential interaction with sodium intake. RESULTS: During a median follow-up of 10.4 (6.2-11.4) years, 641 (13%) participants developed increased albuminuria, and 268 (5%) participants developed reduced eGFR. Plasma 25(OH)D was inversely associated with increased albuminuria (fully adjusted hazard ratio [HR] per SD higher, 0.86; 95% confidence interval [95% CI], 0.78 to 0.95; P=0.003) but not reduced eGFR (HR, 0.99; 95% CI, 0.87 to 1.12; P=0.85). There was interaction between 25(OH)D and sodium intake for risk of developing increased albuminuria (P interaction =0.03). In participants with high sodium intake, risk of developing increased albuminuria was inversely associated with 25(OH)D (lowest versus highest quartile: adjusted HR, 1.81; 95% CI, 1.20 to 2.73, P<0.01), whereas this association was nonsignificant in participants with low sodium intake (HR, 1.29; 95% CI, 0.94 to 1.77; P=0.12). Plasma 1,25(OH)2D was not significantly associated with increased albuminuria or reduced eGFR. CONCLUSIONS: Low plasma 25(OH)D is associated with higher risk of developing increased albuminuria, particularly in individuals with high sodium intake, but not of developing reduced eGFR. Plasma 1,25(OH)2D is not associated with risk of developing increased albuminuria or reduced eGFR.
BACKGROUND AND OBJECTIVES: Low circulating 25-hydroxyvitamin D [25(OH)D] and high sodium intake are both associated with progressive albuminuria and renal function loss in CKD. Both vitamin D and sodium intake interact with the renin-angiotensin-aldosterone system. We investigated whether plasma 25(OH)D or 1,25-dihydroxyvitamin D [1,25(OH)2D] is associated with developing increased albuminuria or reduced renal function and whether these associations depend on sodium intake. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Baseline plasma 25(OH)D and 1,25(OH)2D were measured by liquid chromatography tandem mass spectrometry, and sodium intake was assessed by 24-hour urine collections in the general population-based Prevention of Renal and Vascular End-Stage Disease cohort (n=5051). Two primary outcomes were development of urinary albumin excretion >30 mg/24 h and eGFR (creatinine/cystatin C-based CKD Epidemiology Collaboration) <60 ml/min per 1.73 m(2). Participants with CKD at baseline were excluded. In Cox regression analyses, we assessed associations of vitamin D with developing increased albuminuria or reduced eGFR and potential interaction with sodium intake. RESULTS: During a median follow-up of 10.4 (6.2-11.4) years, 641 (13%) participants developed increased albuminuria, and 268 (5%) participants developed reduced eGFR. Plasma 25(OH)D was inversely associated with increased albuminuria (fully adjusted hazard ratio [HR] per SD higher, 0.86; 95% confidence interval [95% CI], 0.78 to 0.95; P=0.003) but not reduced eGFR (HR, 0.99; 95% CI, 0.87 to 1.12; P=0.85). There was interaction between 25(OH)D and sodium intake for risk of developing increased albuminuria (P interaction =0.03). In participants with high sodium intake, risk of developing increased albuminuria was inversely associated with 25(OH)D (lowest versus highest quartile: adjusted HR, 1.81; 95% CI, 1.20 to 2.73, P<0.01), whereas this association was nonsignificant in participants with low sodium intake (HR, 1.29; 95% CI, 0.94 to 1.77; P=0.12). Plasma 1,25(OH)2D was not significantly associated with increased albuminuria or reduced eGFR. CONCLUSIONS: Low plasma 25(OH)D is associated with higher risk of developing increased albuminuria, particularly in individuals with high sodium intake, but not of developing reduced eGFR. Plasma 1,25(OH)2D is not associated with risk of developing increased albuminuria or reduced eGFR.
Authors: Idris Guessous; William McClellan; David Kleinbaum; Viola Vaccarino; Henry Hugues; Olivier Boulat; Pedro Marques-Vidal; Fred Paccaud; Jean-Marc Theler; Jean-Michel Gaspoz; Michel Burnier; Gérard Waeber; Peter Vollenweider; Murielle Bochud Journal: Clin J Am Soc Nephrol Date: 2015-04-21 Impact factor: 8.237
Authors: John P Forman; Lieneke Scheven; Paul E de Jong; Stephan J L Bakker; Gary C Curhan; Ron T Gansevoort Journal: Circulation Date: 2012-06-18 Impact factor: 29.690
Authors: G F Diercks; A J van Boven; H L Hillege; W M Janssen; J A Kors; P E de Jong; D E Grobbee; H J Crijns; W H van Gilst Journal: Eur Heart J Date: 2000-12 Impact factor: 29.983
Authors: Maartje C J Slagman; Tri Q Nguyen; Femke Waanders; Liffert Vogt; Marc H Hemmelder; Gozewijn D Laverman; Roel Goldschmeding; Gerjan Navis Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: Adrienne Tin; Long Zhang; Michelle M Estrella; Andy Hoofnagle; Casey M Rebholz; Todd T Brown; Frank J Palella; Mallory D Witt; Lisa P Jacobson; Lawrence A Kingsley; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2017-09-05 Impact factor: 2.205
Authors: Charlotte A Keyzer; G Fenna van Breda; Marc G Vervloet; Maarten A de Jong; Gozewijn D Laverman; Marc H Hemmelder; Wilbert M T Janssen; Hiddo J Lambers Heerspink; Arjan J Kwakernaak; Stephan J L Bakker; Gerjan Navis; Martin H de Borst Journal: J Am Soc Nephrol Date: 2016-11-17 Impact factor: 10.121
Authors: Joseph Lunyera; Clemontina A Davenport; Jane Pendergast; Solomon K Musani; Nrupen A Bhavsar; Mario Sims; Stanford Mwasongwe; Myles Wolf; Clarissa J Diamantidis; L Ebony Boulware; Julia J Scialla Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Alexander Teumer; Giovanni Gambaro; Tanguy Corre; Murielle Bochud; Peter Vollenweider; Idris Guessous; Marcus E Kleber; Graciela E Delgado; Stefan Pilz; Winfried März; Catriona L K Barnes; Peter K Joshi; James F Wilson; Martin H de Borst; Gerjan Navis; Pim van der Harst; Hiddo J L Heerspink; Georg Homuth; Karlhans Endlich; Matthias Nauck; Anna Köttgen; Cristian Pattaro; Pietro Manuel Ferraro Journal: Nephrol Dial Transplant Date: 2018-12-01 Impact factor: 7.186
Authors: Jacob M Taylor; Lyanne M Kieneker; Martin H de Borst; Sipke T Visser; Ido P Kema; Stephan J L Bakker; Ron T Gansevoort Journal: Kidney Int Rep Date: 2016-12-31
Authors: Ryanne S Hijmans; Pragyi Shrestha; Kwaku A Sarpong; Saleh Yazdani; Rana El Masri; Wilhelmina H A de Jong; Gerjan Navis; Romain R Vivès; Jacob van den Born Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240